WO2021142920A1 - 一种治疗肺癌的中药组合物及其制剂和应用 - Google Patents
一种治疗肺癌的中药组合物及其制剂和应用 Download PDFInfo
- Publication number
- WO2021142920A1 WO2021142920A1 PCT/CN2020/080112 CN2020080112W WO2021142920A1 WO 2021142920 A1 WO2021142920 A1 WO 2021142920A1 CN 2020080112 W CN2020080112 W CN 2020080112W WO 2021142920 A1 WO2021142920 A1 WO 2021142920A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- cynomorium
- medicine composition
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 19
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 19
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims description 103
- 241000500128 Cynomorium Species 0.000 claims description 72
- 241001165494 Rhodiola Species 0.000 claims description 57
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000000706 filtrate Substances 0.000 claims description 38
- 230000005012 migration Effects 0.000 claims description 36
- 238000013508 migration Methods 0.000 claims description 36
- 206010023774 Large cell lung cancer Diseases 0.000 claims description 33
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 21
- 230000035755 proliferation Effects 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 241000190633 Cordyceps Species 0.000 abstract description 22
- 239000008820 moutan cortex Substances 0.000 abstract description 15
- 239000000463 material Substances 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 44
- 230000000259 anti-tumor effect Effects 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 25
- 239000007788 liquid Substances 0.000 description 25
- 238000010586 diagram Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 238000010411 cooking Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 244000042430 Rhodiola rosea Species 0.000 description 16
- 235000003713 Rhodiola rosea Nutrition 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 12
- 240000005001 Paeonia suffruticosa Species 0.000 description 11
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 238000006748 scratching Methods 0.000 description 9
- 230000002393 scratching effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000002386 leaching Methods 0.000 description 6
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 235000015241 bacon Nutrition 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000804384 Cynomorium songaricum Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition, as well as its application, and at the same time discloses a traditional Chinese medicine preparation.
- Cordyceps sinensis also known as Cordyceps sinensis, is a complex of Cordyceps sinensis fungus and Hepidiaceae larvae.
- Cordyceps sinensis is formed by connecting the worm body and the fungus seat that grows from the head of the worm.
- the body shape is like a silkworm, 3-5cm long, 0.3-0.8cm in diameter, dark yellow to yellowish brown on the surface, with 20-30 ring patterns, the ring pattern near the head is thinner, and the head is reddish brown; 8 pairs of feet, middle part 4 pairs are more obvious; brittle, easy to break, slightly flat section, pale yellowish white.
- the pedestal is slender and cylindrical, with a length of 4-7cm and a diameter of about 0.3cm.
- the surface is dark brown to tan, with fine longitudinal wrinkles, and the upper part is slightly enlarged; the texture is flexible and the cross section is white.
- Cordyceps has a slightly fishy smell and a slightly bitter taste. According to chemical analysis, Cordyceps contains 25%-30% crude protein, D-mannitol (cordycepic acid) 7%-29%, fat 8.4%, and also contains adenosine, ergosterol, vitamins, cordyceps polysaccharides, a variety of amino acids, etc. .
- Cordyceps sinensis is one of China's three major tonics alongside ginseng and deer antler, and has a very long history of application in China.
- the ancient Chinese medicine "Picture Book” records Cordyceps "clears lung heat, cures lung diseases, bacon disease”; “Notes on Golden Juice Manlu Aquarius” contains: “Cordyceps sinensis tastes sweet and warm. Nourishes kidney yin, nourishes lungs, cures lung diseases, bacon "Bacon” is a Vietnamese medical term meaning water and soil.
- Bacon disease is a variety of allergic diseases caused by inconsistent water and soil, such as allergic rhinitis, asthma, allergic gastroenteritis, allergic dermatitis and other allergic diseases; Wu Yiluo of the Qing Dynasty "Ben Cao Congxin” records: protect lung qi, strengthen the body, nourish the kidney and nourish essence.
- Cordyceps sinensis Many researches have been carried out on Cordyceps sinensis, and a variety of compatible pharmaceutical compositions of Cordyceps sinensis have been developed.
- the authorized patent with the announcement number CN102716320B discloses a pharmaceutical composition for the treatment of non-small cell lung cancer, which includes 11 Chinese medicines such as Cordyceps sinensis and Schisandra.
- the pharmaceutical composition has an effect on the growth of human lung cancer A549 cell transplanted tumors in nude mice. Antagonism.
- the patent application with publication number CN104547525A also discloses a pharmaceutical composition for anti-non-small cell lung cancer, which is made up of 19 traditional Chinese medicines including astragalus, Radix Pseudostellariae, Ophiopogon japonicus, Schisandra, Cordyceps sinensis, etc.
- the pharmaceutical composition is verified by experiments. It also has an inhibitory effect on the growth of human lung cancer A549 cell transplanted tumors in nude mice.
- the existing medicinal compositions for treating lung cancer with Cordyceps participating in compatibility have complex formulations. On the one hand, too many components can easily increase toxicity, and on the other hand, too many components will increase the difficulty of subsequent preparation processes, and Increase production costs.
- a technical solution adopted by the present invention is: a traditional Chinese medicine composition prepared from raw materials comprising the following parts by weight: 1-10 parts of Cordyceps sinensis, 4-20 parts of Rhodiola, and Cynomorium 3. ⁇ 15 parts, 2 ⁇ 10 parts of Cortex Moutan.
- the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of Cordyceps sinensis, 4-20 parts of Rhodiola, 3-15 parts of Cynomorium, and 2-10 parts of Cortex Moutan.
- the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1 to 4 parts of Cordyceps sinensis, 4 to 16 parts of Rhodiola, 3 to 9 parts of Cynomorium, and 2 to 6 parts of Cortex Moutan; more preferably It is prepared from the following raw materials in parts by weight: 3 to 4 parts of Cordyceps sinensis, 12 to 16 parts of Rhodiola, 6 to 9 parts of Cynomorium, and 4 to 6 parts of Cortex Moutan.
- the present invention also provides a method for preparing the traditional Chinese medicine composition, which is prepared by solvent extraction after mixing the raw materials.
- each of the raw materials is dry powder.
- the traditional Chinese medicine composition is prepared by a method including the following steps: mixing the raw materials, soaking in a solvent, decocting, filtering to retain the filtrate, concentrating, and spray drying.
- the solvent is an organic solvent or water, more preferably methanol, ethanol or water.
- the present invention also provides a preparation made from the traditional Chinese medicine composition; preferably, the preparation is a powder.
- the present invention further discloses the use of the traditional Chinese medicine composition and traditional Chinese medicine preparation.
- the lung cancer is non-small cell lung cancer.
- the use of the traditional Chinese medicine composition or the preparation in the preparation of a medicament for inhibiting the proliferation and/or migration of human large cell lung cancer cells is not limited.
- the present invention also provides an inhibitor for inhibiting the proliferation and/or migration of human large cell lung cancer cells, comprising the traditional Chinese medicine composition or the preparation.
- the invention provides a traditional Chinese medicine composition for treating lung cancer.
- Tumor is a local manifestation of a systemic disease.
- the TCM theory believes that the occurrence and development of tumors are caused by lack of righteousness in the human body, external evil and internal invasion, and poor emotions, resulting in imbalance of collective Yin and Yang, imbalance of internal organs, imbalance of Qi and blood, and blockage of meridians and collaterals. .
- the present invention adopts the method of replenishing the lungs and kidneys, promoting blood circulation and removing blood stasis according to the theory of traditional Chinese medicine, using rhodiola to nourish qi and activating blood as the monarch medicine, cynomorium tonifying the kidney and yang, nourishing essence and blood as the minister medicine, and using Mudanpi to clear heat and promote blood Resolving blood stasis and fresh Cordyceps (breeding products, that is, artificially breeding products) are used as adjuvants to invigorate the lungs and kidneys, and the traditional Chinese medicine anti-tumor compound preparation of the invention is prepared.
- the raw materials used are introduced as follows.
- Rhodiola is the dry root and rhizome of Rhodiola crenulata (Hook.f.et Thoms.)H.Ohba.), a plant of the Crassulaceae family. After the flower stems are withered in autumn, they are excavated, the rough bark is removed, washed, and dried. Rhodiola is fragrant in weather, slightly bitter and sweet afterwards. Nature and flavor return to classics: sweet, bitter, and flat. Return to the lung and heart meridian. Functions and indications: invigorating qi and activating blood circulation, clearing the pulse and relieving asthma. It is used for qi deficiency and blood stasis, chest pain, heartache, stroke and hemiplegia, fatigue and asthma.
- Cynomorium is the dry fleshy stem of Cynomorium songaricum Rupr. Excavate in spring, remove the inflorescence, cut into sections, and dry. Cynomorium has a slight qi, sweet and astringent. Nature and flavor return to classics: sweet, warm. Return to the liver, kidney, and large intestine meridian. Functions and indications: invigorating kidney-yang, nourishing essence and blood, moistening the intestines and laxative. It is used for deficiency of kidney yang, deficiency of essence and blood, weak waist and knee atrophy, impotence smoothness, dry intestines and constipation.
- Paeonia suffruticosa is the dried root bark of the peony (Paeonia suffruticosa Andr.) of the Ranunculaceae family.
- the roots are excavated in autumn, fine roots and sand are removed, the root bark is peeled, the rough bark is sun-dried, the wood heart is removed, and the sun-dried.
- the skin of peony has a fragrant, slightly bitter and astringent taste. Nature and flavor return to menstruation: bitter, pungent, slightly cold.
- Fresh Cordyceps sinensis (breeding product) is a fresh or dried complex of the larvae of the ergot family fungus Ophicordyceps sinensis (Berk.) Sacc. parasitizing on the larvae of Hepidiaceae insect larvae and the larval carcass under simulated original ecological conditions. Slightly fishy smell and slightly bitter taste. Nature and flavor return to classics: sweet, flat. Return to the lung and kidney meridian. Functions and indications: nourish the lungs and kidneys, stop bleeding and resolve phlegm.
- the cell activity experiment of the present invention proves that the traditional Chinese medicine composition can obviously inhibit the proliferation and migration of human large cell lung cancer cells (H460), and has anti-H460 tumor cell activity.
- H460 human large cell lung cancer cells
- the above experiments prove that the traditional Chinese medicine composition provided by the present invention has obvious synergistic effects.
- Cordyceps sinensis combined with Rhodiola rosea, Cynomorium cynomorium and Moutan cortex with anti-tumor activity can exert a synergistic effect on the inhibition of the proliferation and migration of H460 tumor cells. Synergistic effect.
- the Chinese medicine composition of the present invention is expected to be used as an alternative in the screening of Chinese patent medicines for tumors, and provides an excellent source of formulas for the development of new Chinese medicines.
- the traditional Chinese medicine composition provided by the present invention can reduce the types of traditional Chinese medicines in the composition while achieving the effect of inhibiting tumor activity, has simple compatibility, avoids the toxic and side effects that may be caused by too many components, and can be further developed for clinical use.
- the invention also provides a traditional Chinese medicine preparation, which is prepared by the preparation process of water extraction, concentration and spray drying.
- the preparation process is as follows:
- Purified water is preferred as the leaching solvent.
- Water has good solubility for polar components such as alkaloids, glycosides, tannins, water-soluble organic acids, amino acids, inorganic salts, etc.; the preferred soaking time is 30 minutes, Facilitate the dissolution and leaching of active ingredients;
- Fig. 1 is a comparative diagram of the effect of the dry powder of Cordyceps sinensis in different concentrations of Comparative Example 1 on the migration and scratching of human large cell lung cancer cells H460 in the present invention
- Comparative Example 8 is a comparative diagram of the effects of the mixed dry powder of Rhodiola, Cynomorium, and Moutan Cortex provided by Comparative Example 8 with different concentrations in the present invention on the migration and scratching of human large cell lung cancer cells H460;
- Figure 3 is a comparison diagram of the effect of the anti-tumor compound dry powder provided in Example 1 of the present invention at different concentrations on the migration and scratching of human large cell lung cancer cells H460;
- Example 5 is a comparison diagram of the effect of the anti-tumor compound dry powder provided in Example 4 of the present invention at different concentrations on the migration and scratching of human large cell lung cancer cells H460;
- Example 7 is a comparison diagram of the effect of the anti-tumor compound dry powder provided in Example 5 of the present invention at different concentrations on the migration and scratching of human large cell lung cancer cells H460;
- Example 8 is a comparative diagram of the effect of the anti-tumor compound dry powder provided in Example 2 of the present invention on the migration and scratching of human large cell lung cancer cells H460;
- Example 9 is a histogram of the scratch area change ratio of the anti-tumor compound dry powder provided in Example 2 of the present invention on the migration scratch of human large cell lung cancer cell H460;
- Example 10 is a comparative diagram of the effect of the anti-tumor compound dry powder provided in Example 3 of the present invention on the migration and scratching of human large cell lung cancer cells H460;
- Fig. 11 is a histogram of the scratch area change ratio of the anti-tumor compound dry powder provided in Example 3 of the present invention on the migration scratch of human large cell lung cancer cell H460.
- This embodiment provides a traditional Chinese medicine composition, which is made of the following raw materials in parts by weight: 4 parts of Rhodiola, 3 parts of Cynomorium, 2 parts of Cortex Moutan, and 1 part of Cordyceps sinensis.
- This embodiment provides a traditional Chinese medicine composition, which is made of the following raw materials in parts by weight: 10 parts of Rhodiola, 5 parts of Cynomorium, 4 parts of Cortex Moutan, and 2 parts of Cordyceps sinensis.
- This embodiment provides a traditional Chinese medicine composition, which is made of the following raw materials by weight: 16 parts of Rhodiola, 7 parts of Cynomorium, 5 parts of Cortex Moutan, and 3 parts of Cordyceps sinensis.
- This embodiment provides a traditional Chinese medicine composition, which is made of the following raw materials in parts by weight: 20 parts of Rhodiola, 15 parts of Cynomorium, 10 parts of Cortex Moutan, and 10 parts of Cordyceps sinensis.
- This embodiment provides a traditional Chinese medicine composition, which is made of the following raw materials by weight: 10 parts of Rhodiola, 9 parts of Cynomorium, 6 parts of Cortex Moutan, and 5 parts of Cordyceps sinensis.
- Rhodiola and Cynomorium mixed dry powder Prepare Rhodiola and Cynomorium mixed dry powder.
- the weight parts of Rhodiola and Cynomorium are 4 parts of Rhodiola and 3 parts of Cynomorium.
- Rhodiola rosea and tree peony bark A mixed dry powder of Rhodiola rosea and tree peony bark is prepared. Among them, the weight parts of Rhodiola and Moutan bark are 4 parts of Rhodiola rosea and 2 parts of Moutan bark.
- a mixed dry powder of Rhodiola rosea and Cordyceps sinensis is prepared.
- the parts by weight of Rhodiola and Cordyceps are 4 parts of Rhodiola and 1 part of Cordyceps.
- Cynomorium and Cordyceps A mixed dry powder of Cynomorium and Cordyceps was prepared. Among them, the weight parts of Cynomorium and Cordyceps are 3 parts of Cynomorium and 1 part of Cordyceps.
- Rhodiola rosea A mixed dry powder of Rhodiola rosea, Cynomorium cynomorium, and Paeonia suffruticosa bark was prepared.
- the weight parts of Rhodiola, Cynomorium, and Moutan Cortex are 4 parts of Rhodiola, 3 parts of Cynomorium, and 2 parts of Cortex Moutan.
- Rhodiola rosea A mixed dry powder of Rhodiola rosea, Cynomorium cynomorium, and Paeonia suffruticosa bark was prepared.
- the weight parts of Rhodiola, Cynomorium, and Moutan Cortex are 10 parts of Rhodiola, 5 parts of Cynomorium, and 4 parts of Cortex Moutan.
- Rhodiola rosea A mixed dry powder of Rhodiola rosea, Cynomorium cynomorium, and Paeonia suffruticosa bark was prepared.
- the weight parts of Rhodiola, Cynomorium and Moutan Cortex are 16 parts of Rhodiola, 7 parts of Cynomorium, and 5 parts of Cortex Moutan.
- Rhodiola rosea A mixed dry powder of Rhodiola rosea, Cynomorium cynomorium, and Paeonia suffruticosa bark was prepared.
- the weight parts of Rhodiola, Cynomorium, and Moutan Cortex are 20 parts of Rhodiola, 15 parts of Cynomorium, and 10 parts of Cortex Moutan.
- Rhodiola rosea A mixed dry powder of Rhodiola rosea, Cynomorium cynomorium, and Paeonia suffruticosa bark was prepared.
- the weight parts of Rhodiola, Cynomorium, and Moutan Cortex are 10 parts of Rhodiola, 9 parts of Cynomorium, and 6 parts of Cortex Moutan.
- the cell viability test was performed on the anti-tumor compound dry powder provided in the above examples.
- the specific experiment process is as follows.
- the cells in the culture flask grow to 85%-95% confluence, the cells are subcultured; discard the old culture medium, wash twice with PBS, add 2ml 0.25% trypsin digestion solution, after the cells become round and float, add 4ml culture solution Terminate the digestion, then transfer to a 15ml sterile centrifuge tube, centrifuge at 1000r/min for 4min, discard the supernatant, and transfer to a new sterile culture flask at a ratio of 1:4.
- H460 cells in logarithmic growth phase were collected, and counted with RPMI-1640 complete medium and resuspended cells, cells are seeded seeding density of 104 cells / well, a total of 100 L; 24 incubated at 37 °C, 5% CO 2 conditions Hour.
- Co-cultured cell growth inhibition rate % [(Ac-As)/(Ac-Ab)] ⁇ 100%;
- Table 1 shows the inhibitory rate and IC 50 value of different concentrations of Comparative Example 1 Cordyceps dry powder on the proliferation of human large cell lung cancer cells H460.
- Table 2 shows the Rhodiola ⁇ Cynomorium mixed dry powder provided by Comparative Example 2 at different concentrations, the Rhodiola rosea ⁇ Cordyceps sinensis mixed dry powder provided by Comparative Example 3, the Rhodiola rosea ⁇ Cordyceps sinensis mixed dry powder provided by Comparative Example 4, and Comparative Example 5
- Table 3 shows the inhibitory rate and IC 50 value of the mixed dry powder of Rhodiola, Cynomorium, and Moutan Cortex provided by Comparative Example 8 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- Table 4 shows the inhibition rate and IC 50 value of the anti-tumor compound dry powder provided in Example 1 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- Table 5 shows the inhibitory rate and IC 50 value of the mixed dry powder of Rhodiola, Cynomorium and Moutan bark provided by Comparative Example 11 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- Table 6 shows the inhibition rate and IC 50 value of the anti-tumor compound dry powder provided in Example 4 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- Table 7 shows the inhibitory rate and IC 50 value of the mixed dry powder of Rhodiola, Cynomorium, and Moutan Cortex provided by Comparative Example 12 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- Table 8 shows the inhibition rate and IC 50 value of the anti-tumor compound dry powder provided in Example 5 at different concentrations on the proliferation of human large cell lung cancer cells H460.
- the dry powder made by mixing any two or three of Cordyceps sinensis has a significant increase in the inhibition rate of H460 cell proliferation and a significant decrease in IC 50 value, indicating that the compatibility of Rhodiola rosea, Cynomorium sylvestris, Paeonia suffruticosa and Cordyceps sinensis has achieved synergistic effect.
- the mixed dry powder made has an inhibitory effect on the proliferation of lung cancer cells H460. Among them, the anti-tumor compound of Example 1 has the best effect.
- the H460 cells in the logarithmic growth phase were digested with 0.25%-EDTA trypsin and pipetted into a single cell suspension.
- the cell concentration was adjusted to 5 ⁇ 10 5 cells/mL, and 1 mL/well was seeded in a 6-well plate. Incubate for 24 hours in a 37°C, 5% CO 2 incubator.
- the comparison diagram of the effect of the anti-tumor compound dry powder provided in Example 2 on the migration and scratch of human large cell lung cancer cells H460 is shown in Figure 8, the histogram of the change in scratch area is shown in Figure 9, and the data of the change in the area of migration and scratch is shown in the table. 16.
- the sample concentrations of Comparative Example 1, Comparative Example 9 and Example 2 used in Table 16 are all 3 mg/mL.
- control group is a blank control, cultured with RPMI-1640 complete medium without adding any drugs.
- the comparative diagram of the effect of the anti-tumor compound dry powder provided in Example 3 on the migration and scratch of human large cell lung cancer cells H460 is shown in Figure 10
- the histogram of the change in scratch area is shown in Figure 11
- the data of the change in the area of migration and scratch is shown in the table. 17.
- the sample concentrations of Comparative Example 1, Comparative Example 10, and Example 3 used in Table 17 are all 3 mg/mL.
- control group is a blank control, cultured with RPMI-1640 complete medium without adding any drugs.
- the experimental animals were SPF-grade C57BL/6 male mice from Slack, Hunan, weighing 20-22g. After the animals are purchased, they are placed in the quarantine room for observation for a week, and then transferred to the SPF laboratory for breeding.
- Example 1 Take the anti-tumor compound dry powder of Example 1 and use 0.9% normal saline to prepare drug concentrations of 30, 50, and 100 mg/mL, respectively, and administer by gavage.
- the gavage volume is 10 mL/kg, and the drug is administered once a day.
- Cisplatin is administered by intraperitoneal injection every other day, the injection volume is 1 mL/kg, and the administration dose is 2 mg/kg.
- A, B, C, D, and E representing the model group
- the cisplatin group (2mg/kg)
- the low-dose Chinese medicine antitumor compound group 300mg/kg
- the Chinese medicine The medium-dose group of anti-tumor compound preparation (500 mg/kg) and the high-dose group of anti-tumor compound preparation of Chinese medicine (1000 mg/kg), 15 animals in each group, a total of 75 animals.
- mouse Lewis lung cancer cells were cultured with DMEM medium containing 10% fresh fetal bovine serum. In the logarithmic growth phase, the cells were routinely digested with 0.25% pancreatin, and the tumor density was adjusted to 1 ⁇ 10 7 /mL cell suspension.
- mice in the 8-part group was subcutaneously inoculated with 1 ⁇ 10 7 Lewis lung cancer cells under the armpit of the left extremity, and was administered according to the above-mentioned administration method and dosage at the same time.
- each mouse of group B was injected with 2mg/kg cisplatin solution, which was administered every other day for a total of 20 days. The administration mode and dosage of the other groups were unchanged, and the rats were given by intragastric administration for 20 days.
- mice in groups C, D, and E were weighed every day and their mental status was observed. On the 7th day, observe whether the mice in the above 5 groups are dead. On days 1, 3, 13, 15, 17, and 20 after inoculation, the animal tumor measurement and tracking system was used to measure the longest diameter and shortest diameter of the tumor (cm) with an electronic digital caliper.
- Tumor volume longest tumor diameter ⁇ shortest diameter ⁇ The shortest path/2.
- the mice in each group were weighed, and the mice were sacrificed by removing the cervical spine. The tumor mass of the mice was completely removed and weighed, and the tumor inhibition rate was calculated.
- Tumor inhibition rate (%) (average tumor weight of the control group-average tumor weight of the administration group) ⁇ 100%/average tumor weight of the control group. After standardization of all experimental data, GraphPad Prism 7 was used for statistical analysis and graphing.
- Example 1 the anti-tumor compound of Example 1 at different concentrations did not affect the normal body weight and growth of the mice.
- the mice in each group were in good mental state and did not die.
- the anti-tumor compound had no obvious toxic and side effects.
- the high-dose Example 1 anti-tumor compound significantly inhibited the tumor volume and weight of tumor-bearing mice, and the tumor-inhibiting effect was equivalent to that of the positive control drug cisplatin.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 肿瘤重量(g) | 抑瘤率(%) |
模型组 | 2.63±1.47 | - |
顺铂组 | 1.40±0.85* | 46.79 |
低剂量组(300mg/kg) | 2.03±0.35 | 22.81 |
中剂量组(500mg/kg) | 1.81±0.57 | 31.00 |
高剂量组(1000mg/kg) | 1.53±0.86 # | 41.83 |
Claims (10)
- 一种中药组合物,其特征在于,由包括以下重量份的原料药制备而成:冬虫夏草1~10份,红景天4~20份,锁阳3~15份,牡丹皮2~10份。
- 根据权利要求1所述的中药组合物,其特征在于,由以下重量份的原料药制备而成:冬虫夏草1~10份,红景天4~20份,锁阳3~15份,牡丹皮2~10份。
- 根据权利要求2所述的中药组合物,其特征在于,由以下重量份的原料药制备而成:冬虫夏草1~4份,红景天4~16份,锁阳3~9份,牡丹皮2~6份;优选地,由以下重量份的原料药制备而成:冬虫夏草3~4份,红景天12~16份,锁阳6~9份,牡丹皮4~6份。
- 根据权利要求1~3任意一项所述的中药组合物,其特征在于,所述中药组合物是将各原料药混合后,经溶剂提取制得;优选地,所述各原料药均为干燥药粉。
- 根据权利要求4所述的中药组合物,其特征在于,所述中药组合物由包括以下步骤的方法制备而成:将各原料药混合,在溶剂中浸泡、煎煮,过滤留取滤液,浓缩、喷雾干燥。
- 根据权利要求5所述的中药组合物,其特征在于,所述溶剂为有机溶剂或水,优选为甲醇、乙醇或水。
- 包含权利要求1~6任意一项所述中药组合物的制剂;优选地,所述制剂为粉剂。
- 权利要求1~6任意一项所述中药组合物或权利要求7所述制剂在制备治疗肺癌的药物中的用途;优选地,所述肺癌为非小细胞肺癌。
- 权利要求1~6任意一项所述中药组合物或权利要求7所述制剂在制备用于抑制人大细胞肺癌细胞增殖和/或迁移药物中的用途。
- 一种抑制人大细胞肺癌细胞增殖和/或迁移的抑制剂,其特征在于,包含权利要求1~6任意一项所述中药组合物或权利要求7所述 制剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010059232.X | 2020-01-19 | ||
CN202010059232 | 2020-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021142920A1 true WO2021142920A1 (zh) | 2021-07-22 |
Family
ID=76809489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/080112 WO2021142920A1 (zh) | 2020-01-19 | 2020-03-19 | 一种治疗肺癌的中药组合物及其制剂和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113134034A (zh) |
WO (1) | WO2021142920A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057473A (zh) * | 2020-09-22 | 2020-12-11 | 郭国康 | 一种关于肺病肺癌增强肺活量的组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101301413A (zh) * | 2007-07-31 | 2008-11-12 | 四川回春堂生物科技有限公司 | 虫草红景天胶囊及其制备方法 |
CN101380350A (zh) * | 2008-09-30 | 2009-03-11 | 苟春虎 | 虫草救心复方胶囊 |
-
2020
- 2020-03-19 CN CN202010194434.5A patent/CN113134034A/zh not_active Withdrawn
- 2020-03-19 WO PCT/CN2020/080112 patent/WO2021142920A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101301413A (zh) * | 2007-07-31 | 2008-11-12 | 四川回春堂生物科技有限公司 | 虫草红景天胶囊及其制备方法 |
CN101380350A (zh) * | 2008-09-30 | 2009-03-11 | 苟春虎 | 虫草救心复方胶囊 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057473A (zh) * | 2020-09-22 | 2020-12-11 | 郭国康 | 一种关于肺病肺癌增强肺活量的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113134034A (zh) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374538C (zh) | 五脏滋补酒及其制备工艺 | |
JP5946457B2 (ja) | 漢方薬組成物の、肉体疲労の緩和及び予防治療のための健康食品や医薬品の調製への応用 | |
CN112190593B (zh) | 一种抑制trpv1通路的多糖组合物及其制备方法和应用 | |
CN1275639C (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物及其制备方法 | |
WO2010028075A1 (en) | Herbal composition for treating cancer | |
CN113278535A (zh) | 一种灵芝新菌种zl167及其新用途 | |
KR20190124197A (ko) | 종양 치료용 한약 조성물 및 그 제조방법 및 응용 | |
WO2021142920A1 (zh) | 一种治疗肺癌的中药组合物及其制剂和应用 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN108452240B (zh) | 一种抗肿瘤的中药组合物及其应用 | |
CN108175801B (zh) | 具有化学性肝损伤保健功能的中药组合物及其制备方法 | |
CN101637563B (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备工艺 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN101711790A (zh) | 一种用于治疗肝癌的野生核桃楸树皮水提取物 | |
CN110882382A (zh) | 一种含有sod组份的养生药酒及其制备方法 | |
KR102559079B1 (ko) | 한약재 복합 추출물을 유효 성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 | |
CN111568935B (zh) | 赤苍藤提取物在制备抗肿瘤药物中的应用 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN102631487B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN102000303B (zh) | 一种抑制肿瘤的中药复方制剂 | |
CN102631486B (zh) | 一种保健组合物 | |
CN108743654B (zh) | 一种用于治疗缺血性心脏病的中药组合物及其制备方法和应用 | |
CN1961895B (zh) | 一种新的抗癌药物组合物及其制备方法 | |
CN105998448A (zh) | 提高免疫力的桑葚口服液制备方法及其口服液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20913476 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20913476 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20913476 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.02.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20913476 Country of ref document: EP Kind code of ref document: A1 |